Xenograft are the cells of one species transplanted to another species.
With advances in genome sequencing, cancer treatments have increasingly sought to leverage the idea of "synthetic lethality," exploiting cancer-specific genetic defects to identify targets that are uniquely essential to the survival of cancer cells.
Scientists have uncovered the genomic signature to explain why 18F-FDG imaging performs better than PSMA-targeted imaging for prostate cancer patients with low or no expression of the prostate-specific membrane antigen (PSMA).
Researchers have developed a new pair of agents that show exceptional effectiveness for precision diagnosis and treatment of prostate cancer in preclinical studies.
Scientists at St. Jude Children's Research Hospital have created orthotopic patient-derived xenograft (O-PDX) models representing a variety of pediatric brain tumor types.
News-Medical talks to Professor David Thomas about his recent research identifying the mechanisms behind cancer cells developing resistance to drugs.
TissueGnostics is pleased to announce achieving a new level of confidence within the international biomedical research community. As of May 2020, TissueGnostics has been referenced in over 1,500 individual research publications. High impact research made possible by TissueGnostics, emerging from 59 countries on 6 continents, results in a sum impact factor of 8,700.
Seed investor CincyTech announced the formation of Kurome Therapeutics ("Kurome"), a preclinical stage company developing novel therapies targeting cancer cells' adaptive resistance mechanisms beginning with hematopoietic, or blood cell, cancers.
The full title of the research is "The study of the mechanisms of effectiveness of T-cells CAR-T towards solid tumors"; it was supported by nonprofit RakFond (Cancer Fund) and CyStoreLab (a resident of Skolkovo).
The cover for issue 11 of Oncotarget features Figure 6, "Effects of AZD8186 in combination with anti-PD1 on syngeneic models," by Owusu-Brackett, et al.
New discovery in breast cancer could lead to better strategies for preventing the spread of cancer cells to other organs in the body, effectively reducing mortality in breast cancer patients.
An international team of researchers led by scientists at Baylor College of Medicine has new insights into the function of neurofibromin, a tumor suppressor produced by the NF1 gene.
Loss of an important tumor-suppressing gene allows head and neck cancer to spin off signals to nearby nerves, changing their function and recruiting them to the tumor, where they fuel growth and cancer progression, researchers from The University of Texas MD Anderson Cancer Center report in the journal Nature today.
Oxygen in cancer tumors is known to be a major factor that helps radiation therapy be successful. Hypoxia, or starvation of oxygen, in solid tumors is also thought to be an important factor in resistance to therapy.
To establish a molecular signature of this resistance in ovarian cancer, the authors developed preclinical tumor models of adaptive resistance to chronic anti-VEGF treatment.
A new study has shown that regular use of aspirin may protect against heart disease, reduce colorectal tumor growth and prevent relapse.
The Department of Neurosurgery at the Icahn School of Medicine at Mount Sinai has received more than $10 million in federal funding for several projects focusing on brain tumor research.
In laboratory experiments, a metabolic inhibitor was able to kill a variety of human cancer cells of the skin, breast, lung, cervix and soft tissues through a non-apoptotic route -- catastrophic macropinocytosis.
Investigators at Rutgers Cancer Institute of New Jersey have found that a treatment based on a novel cellular product programmed to deliver an overabundance of chimeric antigen receptor causes cell death in non-Hodgkin lymphoma models that are sensitive or resistant to standard therapies.
Gene expression profiling and other analyses conducted by Rutgers Cancer Institute of New Jersey researchers and colleagues examining drug resistance to a common antibody therapy for non-Hodgkin lymphoma have identified calcium signaling as a novel and exploitable target in overcoming this treatment obstacle.
78 TNBC biopsies from patients with different responses to chemotherapy were analysed for API-5 expression before any treatment.